The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Another brilliant and exciting interview with Dr Khan , CEO of Hevolution with Longevity Technology who are invested in Genflow.
Dr Khan confirms there will be major announcements at next week's summit on science, capital and investments, with research institutions and scientists around the world with focus on strategic partnerships and research grants and funding with Academic research institutions and investments into Biotech companies involved with taking the science from Academi research institutions and progressing the R&D towards market....which is exactly what Genflow are doing!!! Gla holders...Excitement building. :-)
Our vision statement is clear: Expand healthy lifespan for the benefit of all’
hTtps://longevity.technology/news/our-vision-statement-is-clear-expand-healthy-lifespan-for-the-benefit-of-all/amp/
"unveil significant investments"
Igniting a New Era in Global Health: Hevolution Foundation Announces Its Inaugural Global Healthspan Summit to Accelerate Scientific Progress for a Rapidly Aging World
NEWS PROVIDED BY
Hevolution Foundation
14 Nov, 2023, 06:24 ET
The largest convening of its kind in Riyadh on Nov. 29 and 30, 2023, the Global Healthspan Summit will catalyze global collaboration around extending healthy years of life, known as "healthspan," and unveil significant investments in the sector.Over 100 international speakers from the US, UK, Egypt, Germany, the Netherlands, Switzerland, Singapore, Spain, and Saudi Arabia and 1000 delegates to convene in Riyadh.With the global population over 60 expected to double to 2 billion by 2050, increasing healthy human healthspan is one of the most urgent issues of our time and could generate savings of $40 trillion per year.With an annual budget of up to $1 billion, Hevolution Foundation is investing in grants for aging research and pioneering impact investments in early-stage biotech.
htTps://www.prnewswire.com/news-releases/igniting-a-new-era-in-global-health-hevolution-foundation-announces-its-inaugural-global-healthspan-summit-to-accelerate-scientific-progress-for-a-rapidly-aging-world-301987392.html
He's also one of the speakers at Hevolution's Global Healthspan Summit end of this month.
htTps://hevolution.com/en/web/guest/ghs-speakers
Eric Verdin is on Genflow’s Scientific Advisory Board.
hTtps://loom.ly/HqJZHZs?trk=organization_guest_main-feed-card-text
‘The longevity revolution has the potential to transform healthcare in our lifetime’
1 HOUR AGO
The Buck Institute’s CEO Eric Verdin on why longevity research has transformative power, but the field must tread carefully between the hype and the noise.
htTps://longevity.technology/news/the-longevity-revolution-has-the-potential-to-transform-healthcare-in-our-lifetime/amp/
I wonder if Jim Mellon's Juvenscene is one of the UK investors Eric has been seeing this week, their Executive Chairman has recently made reference to David Sinclair ( much of his R&D is focused on Sirt6 ) and they've been making and planing more investments in the Longevity space....here's hoping Genflow are one of the companies "really doing compelling things right now"....Excitement building on news from Eric on the series of meetings he's had this week with UK investors. Gla :-)
‘We’re at the longevity inflection point – and the explosion is coming.’
Dr Greg Bailey, the Executive Chairman of Juvenescence
To me, being able to invest right now into antiaging and modifying longevity, is exactly at the inflection point that being given the opportunity to invest in generated AI was at three or four years ago – I think it’s gonna have that sort of explosion. We’re seeing it with some of David Sinclair’s work, we’re going to see some astonishing things out of Altos and BioAge. There’s a number of companies that are doing really compelling things right now that are going to explode the space. And I’m not comparing us with the end game – I think generated AI has enormous societal changes and economics associated with it, but just as far as the trajectory of the curve for next two or three years, this, to me, is the time to invest.
hTtps://longevity.technology/news/were-at-the-longevity-inflection-point-and-the-
A Merry Christmas indeed Porter and what could be a Very Prosperous New Year, as Genflow could be the Star share of 2024 as Eric delivers on expectations and takes Genflow into the spotlight and full investor focus.....Exciting times ahead!!! Gl ;-)
Lots of potential news in the pipeline line to add significant UPside, expected soon, and should be very interesting to see if Eric has anything to report next week on the series of meetings he's had this week with potential UK investors. The appointment of the Joint Broker last week speaks volumes, hopefully very much needed as the demand for shares goes into overdrive!!! Gla :-)
hTtps://loom.ly/MeQymHs
Excitement building...Gla holders...On and most definitely UP!!! :-)
A pre-clinical stage Biotech landed $138m for their antibody AAV delivery system, Genflow’s AAV delivery system is focused on the Sirt6 Gene which is thought to be the most important, potent and compelling gene/protein involved in longevity, healthspan and multiple disease targets....Watch this space...Gla holders...On and UP!!!:-)
VectorY lands $138m to target neurodegeneration with vectorized antibodies
12 HOURS AGO
Dutch biotech VectorY Therapeutics has secured $138 million in a Series A financing round to advance its vectorized antibody programs targeting neurodegenerative diseases. The company’s platform combines precise therapeutic antibodies with one-time AAV-based delivery to the central nervous system.
htTps://longevity.technology/news/vectory-lands-138m-to-target-neurodegeneration-with-vectorized-antibodies/amp/
Hi Northeast, we're now approaching a very exciting time with so much potential news in the pipeline, Final in-vivo evaluation results from Genflows four academic research partners, expected by year end, as well as none dilutive research funding intimated by Eric in his last interview at anytime, and now news of possible UK investment partners , from the series of meetings Eric has lined up this week, as well as the huge potential from Hevolution to invest $1 Billion a year into the longevity space with their disclosure of who will be beneficiaries by the end of this month, which would be a game changer if Genflow were in the frame. News also possible on the rest of the pipeline including the status of the planned Werner Syndrome clinical trials and veterinary ( dog ) trials , AAV gene delivery system, further collaborations and so much more. Genflow is primed for lift off!!! Gl ;-)))
Northeast, your 2.7m top up at 1.65p from yesterday has just popped up...Great timing and will be rising in value significantly in the coming days and weeks. Gl :-)
"unveil significant investments"
Let's hope Eric is on the list.:-)
Igniting a New Era in Global Health: Hevolution Foundation Announces Its Inaugural Global Healthspan Summit to Accelerate Scientific Progress for a Rapidly Aging World
NEWS PROVIDED BY
Hevolution Foundation
14 Nov, 2023, 06:24 ET
The largest convening of its kind in Riyadh on Nov. 29 and 30, 2023, the Global Healthspan Summit will catalyze global collaboration around extending healthy years of life, known as "healthspan," and unveil significant investments in the sector.Over 100 international speakers from the US, UK, Egypt, Germany, the Netherlands, Switzerland, Singapore, Spain, and Saudi Arabia and 1000 delegates to convene in Riyadh.With the global population over 60 expected to double to 2 billion by 2050, increasing healthy human healthspan is one of the most urgent issues of our time and could generate savings of $40 trillion per year.With an annual budget of up to $1 billion, Hevolution Foundation is investing in grants for aging research and pioneering impact investments in early-stage biotech.
htTps://www.prnewswire.com/news-releases/igniting-a-new-era-in-global-health-hevolution-foundation-announces-its-inaugural-global-healthspan-summit-to-accelerate-scientific-progress-for-a-rapidly-aging-world-301987392.html
UP we go!!! Gla holders...back to 2p plus on a blink and much much more in the coming days and weeks ahead. :-)
Very interesting Pie -Chart, and extremely encouraging for a significant re-rate or two on news of any major investors Eric can attract, and a very impressive top up Northeast, the current sp is an absolute steel, and soon will be a distant memory as true value is realised as the flow of good news is delivered. Gla :-)
Plenty more UPside momentum on its way in anticipation of material news, which could add significant value with any luck...expected soon....Gla holders...On and UP!!! :-)
The Gaurdian/ Observer
British biotech races US’s ‘buff billionaires’ for secret of eternal youth
The UK excels at ‘longevity research’. Could it become part of an industry that fascinates the wealthiest people in the world?
Julia Kollewe
Sun 5 Nov 2023 07.00 EST
.......
J
London-listed Genflow Biosciences, which last December became the first longevity company to float in Europe, uses a gene variant found in centenarians to try to develop a therapy that can repair DNA damage and extend the time we stay in good health by 25%. It intends to test an experimental therapy on people with an age-related liver disease called NASH within 18 months.
“Some people are lucky to have the good gene, and what we want to do is share that luck with everybody,” said Eric Leire, Genflow’s founder. “So it’s not just a few people who will have the chance to even live to 120 and never see chemotherapy in their life.”
hTtps://www.google.com/amp/s/amp.theguardian.com/business/2023/nov/05/british-biotech-races-uss-buff-billionaires-for-secret-of-eternal-youth
The demand for shares could rise exponentially as good news is delivered in the coming days and weeks. Gla :-)
A bit of a tree shake which I took advantage, with my top up already in profit...Gla holders, good news expected soon which hopefully see a re-rate or two....On and UP!!! ;-)